These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37860180)

  • 41. Reduced E-cadherin expression as a prognostic factor in non-muscle-invasive bladder cancer: A systematic review and meta-analysis.
    Yang T; Fan J; Liang H; He D; Zeng X; Fan J; Wu K
    Prog Urol; 2020 Feb; 30(2):66-74. PubMed ID: 32061496
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of regional versus general anesthesia on recurrence of non-muscle invasive bladder cancer: a systematic review and meta-analysis of eight retrospective cohort studies.
    Wang Y; Song Y; Qin C; Zhang C; Du Y; Xu T
    BMC Anesthesiol; 2023 Jun; 23(1):201. PubMed ID: 37312019
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer.
    Melgarejo-Segura MT; Morales-Martínez A; Yáñez-Castillo Y; Arrabal-Polo MÁ; Gómez-Lechuga P; Pareja-Vílchez M; Jiménez-Moleón JJ; Martín MA
    Urol Oncol; 2023 Apr; 41(4):166-176. PubMed ID: 36328923
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Value of tumour-infiltrating immune cells in predicting response to intravesical BCG in patients with non-muscle-invasive bladder cancer: a systematic review and meta-analysis.
    Kardoust Parizi M; Shariat SF; Margulis V; Mori K; Lotan Y
    BJU Int; 2021 Jun; 127(6):617-625. PubMed ID: 33073457
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic Implications of Treatment Delays for Patients with Non-muscle-invasive Bladder Cancer.
    Ourfali S; Matillon X; Ricci E; Fassi-Fehri H; Benoit-Janin M; Badet L; Colombel M
    Eur Urol Focus; 2022 Sep; 8(5):1226-1237. PubMed ID: 34172421
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Impact of Restaging Transurethral Resection of Bladder Tumor on Survival Parameters in T1 Nonmuscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis.
    Krajewski W; Nowak Ł; Poletajew S; Tukiendorf A; Moschini M; Mari A; Di Trapani E; Xylinas E; Kiełb P; Wełna M; Zdrojowy R
    J Endourol; 2020 Aug; 34(8):795-804. PubMed ID: 32336149
    [No Abstract]   [Full Text] [Related]  

  • 47. Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guérin immunotherapy.
    Lee JY; Diaz RR; Cho KS; Lim MS; Chung JS; Kim WT; Ham WS; Choi YD
    J Urol; 2013 Oct; 190(4):1192-9. PubMed ID: 23648222
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer.
    Bree KK; Hensley PJ; Brooks NA; Matulay J; Li R; Nogueras Gonzalez GM; Navai N; Grossman HB; Matin SF; Dinney CPN; Kamat AM
    BJU Int; 2021 Nov; 128(5):568-574. PubMed ID: 33484074
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy.
    Doisy L; Cimier A; Adypagavane A; Walz J; Marquette T; Maubon T; Rybikowski S; Fakhfakh S; Loverde K; Mottet N; Irani J; Lechevallier E; Rossi D; Gravis G; Pignot G
    Int J Hyperthermia; 2021; 38(1):1633-1638. PubMed ID: 34775896
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
    Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
    Del Giudice F; Barchetti G; De Berardinis E; Pecoraro M; Salvo V; Simone G; Sciarra A; Leonardo C; Gallucci M; Catalano C; Catto JWF; Panebianco V
    Eur Urol; 2020 Jan; 77(1):101-109. PubMed ID: 31699526
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A prospective descriptive 1-year study in France of all BCG therapy dispensations for non-muscle-invasive bladder cancer.
    Neuzillet Y; Leon P; Seisen T; Allory Y; Audenet F; Loriot Y; Masson-Lecomte A; Mejean A; Pradère B; Roumiguié M; Traxer O; Xylinas E; Fournier G; Roupret M
    BJU Int; 2023 May; 131(5):611-616. PubMed ID: 36462164
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Role of Fluorescence In Situ Hybridization in the Surveillance of Non-Muscle Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis.
    Zheng W; Lin T; Chen Z; Cao D; Bao Y; Zhang P; Yang L; Wei Q
    Diagnostics (Basel); 2022 Aug; 12(8):. PubMed ID: 36010354
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and adverse reactions of intra-arterial chemotherapy in patients with bladder cancer: A systematic review and meta-analysis.
    Ji J; Yao Y; Guan F; Sun L; Zhang G
    J Cancer Res Ther; 2022 Dec; 18(7):1884-1893. PubMed ID: 36647946
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR).
    Musat MG; Kwon CS; Masters E; Sikirica S; Pijush DB; Forsythe A
    Clinicoecon Outcomes Res; 2022; 14():35-48. PubMed ID: 35046678
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Intravesical instillation of bacillus Calmette-Guerin for non-muscle invasive bladder cancer: outcomes of 421 patients in a single center].
    Cai T; Lu J; Lin Z; Lup M; Liang H; Qin Z; Ye Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2023 Mar; 43(3):488-494. PubMed ID: 37087596
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Zhao H; Chan VW; Castellani D; Chan EO; Ong WLK; Peng Q; Moschini M; Krajewski W; Pradere B; Ng CF; Enikeev D; Vasdev N; Ekin G; Sousa A; Leon J; Guerrero-Ramos F; Tan WS; Kelly J; Shariat SF; Witjes JA; Teoh JY
    Front Surg; 2021; 8():775527. PubMed ID: 34888347
    [No Abstract]   [Full Text] [Related]  

  • 59. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
    Babjuk M; Burger M; Compérat EM; Gontero P; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Zigeuner R; Capoun O; Cohen D; Escrig JLD; Hernández V; Peyronnet B; Seisen T; Soukup V
    Eur Urol; 2019 Nov; 76(5):639-657. PubMed ID: 31443960
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recurrence- and progression-free survival in intermediate-risk non-muscle-invasive bladder cancer: the impact of conditional evaluation and subclassification.
    Kohada Y; Hayashi T; Hsi RS; Yukihiro K; Sentani K; Goto K; Inoue S; Ohara S; Teishima J; Kajiwara M; Nishisaka T; Yasui W; Black PC; Matsubara A
    BJU Int; 2021 Apr; 127(4):473-485. PubMed ID: 32805763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.